{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T03:47:43Z","timestamp":1778903263306,"version":"3.51.4"},"reference-count":33,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.amjmed.2015.04.034","type":"journal-article","created":{"date-parts":[[2015,6,13]],"date-time":"2015-06-13T07:59:37Z","timestamp":1434182377000},"page":"1195-1203","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Outcomes with Angiotensin-converting Enzyme Inhibitors vs Other Antihypertensive Agents in Hypertensive Blacks"],"prefix":"10.1016","volume":"128","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9485-0652","authenticated-orcid":false,"given":"Sripal","family":"Bangalore","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gbenga","family":"Ogedegbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joyce","family":"Gyamfi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Roy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith","family":"Goldfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Torgersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis","family":"Capponi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nirav R.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjmed.2015.04.034_bib1","series-title":"Hypertension: Clinical management of primary hypertension in adults. NICE guidelines [CG127]","author":"National Institute for Health and Care Excellence","year":"2011"},{"key":"10.1016\/j.amjmed.2015.04.034_bib2","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2015.04.034_bib3","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1097\/01.hjh.0000431740.32696.cc","article-title":"2013 ESH\/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"31","author":"Mancia","year":"2013","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.amjmed.2015.04.034_bib4","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators","volume":"342","author":"Yusuf","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjmed.2015.04.034_bib5","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1161\/01.CIR.0000144474.65922.AA","article-title":"Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program","volume":"110","author":"Solomon","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2015.04.034_bib6","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1475-2840-7-22","article-title":"First-line antihypertensive treatment in patients with pre-diabetes: rationale, design and baseline results of the ADaPT investigation","volume":"7","author":"Zidek","year":"2008","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.amjmed.2015.04.034_bib7","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.1161\/CIRCULATIONAHA.105.540443","volume":"112","author":"Taylor","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2015.04.034_bib8","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1001\/jama.293.13.1595","article-title":"Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril","volume":"293","author":"Wright","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2015.04.034_bib9","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"288","author":"ALLHAT Officers","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2015.04.034_bib10","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1365-2753.2003.00484.x","article-title":"An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors","volume":"10","author":"Morimoto","year":"2004","journal-title":"J\u00a0Eval Clin Pract"},{"key":"10.1016\/j.amjmed.2015.04.034_bib11","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","article-title":"Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial","volume":"288","author":"Wright","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2015.04.034_bib12","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archinte.158.1.26","article-title":"Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry?","volume":"158","author":"Reardon","year":"1998","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.amjmed.2015.04.034_bib13","author":"Dreyer"},{"key":"10.1016\/j.amjmed.2015.04.034_bib14","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/aje\/kwg231","article-title":"Evaluating medication effects outside of clinical trials: new-user designs","volume":"158","author":"Ray","year":"2003","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.amjmed.2015.04.034_bib15","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of propensity score in observational studies for causal effects","volume":"70","author":"Rosenbaum","year":"1983","journal-title":"Biometrika"},{"key":"10.1016\/j.amjmed.2015.04.034_bib16","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1023\/A:1020363010465","article-title":"Using propensity score to help design observational studies: application to the tobacco litigation","volume":"2","author":"Rubin","year":"2001","journal-title":"Health Serv Outcomes Res Methodol"},{"key":"10.1016\/j.amjmed.2015.04.034_bib17","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/eurheartj\/ehi890","article-title":"Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods","volume":"27","author":"Ahmed","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjmed.2015.04.034_bib18","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0895-4356(00)00321-8","article-title":"Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores","volume":"54","author":"Normand","year":"2001","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.amjmed.2015.04.034_bib19","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1023\/A:1020371312283","article-title":"Estimation of causal effects using propensity score weighting: an application to data on right heart catheterization","volume":"2","author":"Hirano","year":"2001","journal-title":"Health Serv Outcomes Res Methodol"},{"key":"10.1016\/j.amjmed.2015.04.034_bib20","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1002\/sim.1903","article-title":"Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study","volume":"23","author":"Lunceford","year":"2004","journal-title":"Stat Med"},{"key":"10.1016\/j.amjmed.2015.04.034_bib21","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1370\/afm.708","article-title":"Race and ethnicity in trials of antihypertensive therapy to prevent cardiovascular outcomes: a systematic review","volume":"5","author":"Park","year":"2007","journal-title":"Ann Fam Med"},{"key":"10.1016\/j.amjmed.2015.04.034_bib22","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/archinte.1995.00430120109013","article-title":"Determinants of black-white differences in the risk of cerebral infarction. The National Health and Nutrition Examination Survey Epidemiologic Follow-up Study","volume":"155","author":"Giles","year":"1995","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.amjmed.2015.04.034_bib23","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1001\/jama.1997.03540400043029","article-title":"End-stage renal disease in African-American and white men. 16-year MRFIT findings","volume":"277","author":"Klag","year":"1997","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2015.04.034_bib24","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/sj.jhh.1000445","article-title":"Hypertension awareness and control in an inner-city African-American sample","volume":"11","author":"Pavlik","year":"1997","journal-title":"J\u00a0Hum Hypertens"},{"key":"10.1016\/j.amjmed.2015.04.034_bib25","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1001\/archinte.1990.00040031707020","article-title":"A\u00a0comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks","volume":"150","author":"Saunders","year":"1990","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.amjmed.2015.04.034_bib26","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1056\/NEJM199304013281303","article-title":"Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents","volume":"328","author":"Materson","year":"1993","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjmed.2015.04.034_bib27","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1161\/01.HYP.26.1.124","article-title":"Differing mechanisms of action of angiotensin-converting enzyme inhibition in black and white hypertensive patients. The Trandolapril Multicenter Study Group","volume":"26","author":"Weir","year":"1995","journal-title":"Hypertension"},{"key":"10.1016\/j.amjmed.2015.04.034_bib28","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1161\/01.HYP.15.1.36","article-title":"Effect of chronic sodium loading on cardiovascular response in young blacks and whites","volume":"15","author":"Falkner","year":"1990","journal-title":"Hypertension"},{"key":"10.1016\/j.amjmed.2015.04.034_bib29","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S0009-9236(96)90155-1","article-title":"Higher incidence of discontinuation of angiotensin converting enzyme inhibitors due to cough in black subjects","volume":"60","author":"Elliott","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.amjmed.2015.04.034_bib30","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1161\/HYPERTENSIONAHA.110.152892","article-title":"Management of high blood pressure in Blacks: an update of the International Society on Hypertension in Blacks consensus statement","volume":"56","author":"Flack","year":"2010","journal-title":"Hypertension"},{"issue":"Suppl 2","key":"10.1016\/j.amjmed.2015.04.034_bib31","first-page":"97S","article-title":"Racial differences in response to low-dose captopril are abolished by the addition of hydrochlorothiazide","volume":"14","year":"1982","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.amjmed.2015.04.034_bib32","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/0002-9149(94)90289-5","article-title":"Effectiveness of enalapril in combination with low-dose hydrochlorothiazide versus enalapril alone for mild to moderate systemic hypertension in black patients","volume":"73","author":"Middlemost","year":"1994","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjmed.2015.04.034_bib33","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa0806182","article-title":"Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients","volume":"359","author":"Jamerson","year":"2008","journal-title":"N\u00a0Engl J Med"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934315004453?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934315004453?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T09:06:51Z","timestamp":1757581611000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934315004453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S0002934315004453"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2015.04.034","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725555236.793529348","asserted-by":"object"}]},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes with Angiotensin-converting Enzyme Inhibitors vs Other Antihypertensive Agents in Hypertensive Blacks","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2015.04.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}